{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:19:54Z","timestamp":1791951594437,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-024-02420-x","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:02:47Z","timestamp":1725368567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Metabolically \u201cextremely unhealthy\u201d obese and non-obese people with diabetes and the risk of cardiovascular adverse events: the Silesia Diabetes - Heart Project"],"prefix":"10.1186","volume":"23","author":[{"given":"Oliwia","family":"Janota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kwiendacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Irlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H. M.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Pia\u015bnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Olejarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"W\u0142osowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Pabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"W\u00f3jcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Gumprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Nabrdalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"issue":"5","key":"2420_CR1","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/0002-8703","volume":"110","author":"WB Kannel","year":"1985","unstructured":"Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985;110(5):1100\u20137. https:\/\/doi.org\/10.1016\/0002-8703. )90224-8. PubMed PMID: 4061265.","journal-title":"Am Heart J"},{"issue":"13","key":"2420_CR2","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","volume":"6","author":"BM Leon","year":"2015","unstructured":"Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246\u201358. https:\/\/doi.org\/10.4239\/wjd.v6.i13.1246. PubMed PMID: 26468341; PubMed Central PMCID: PMC4600176.","journal-title":"World J Diabetes"},{"issue":"1","key":"2420_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","volume":"34","author":"S Klein","year":"2022","unstructured":"Klein S, Gastaldelli A, Yki-J\u00e4rvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11\u201320. https:\/\/doi.org\/10.1016\/j.cmet.2021.12.012. PubMed PMID: 34986330; PubMed Central PMCID: PMC8740746.","journal-title":"Cell Metab"},{"key":"2420_CR4","doi-asserted-by":"publisher","unstructured":"Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbj\u00f6rnsd\u00f3ttir S et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65\u201373. Epub 20081105. https:\/\/doi.org\/10.1007\/s00125-008-1190-x. PubMed PMID: 18985314.","DOI":"10.1007\/s00125-008-1190-x"},{"issue":"11","key":"2420_CR5","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386. https:\/\/doi.org\/10.2337\/dci22-0034. PubMed PMID: 36148880; PubMed Central PMCID: PMC10008140.","journal-title":"Diabetes Care"},{"key":"2420_CR6","unstructured":"Committee ADAPP. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi: 10.2337\/dc24-S002. PubMed PMID: 38078589; PubMed Central PMCID: PMC10725812."},{"issue":"3\u20134","key":"2420_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/ctd\/183052","volume":"3","author":"A Araszkiewicz","year":"2023","unstructured":"Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, Broncel M, Budzy\u0144ski A, Cyganek K, et al. Standards of Care in Diabetes. The position of diabetes Poland\u2013 2024. Curr Top Diabetes. 2023;3(3\u20134):1\u2013348. https:\/\/doi.org\/10.5114\/ctd\/183052.","journal-title":"Curr Top Diabetes"},{"issue":"966","key":"2420_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1136\/pmj.2005.039032","volume":"82","author":"C Daousi","year":"2006","unstructured":"Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82(966):280\u20134. https:\/\/doi.org\/10.1136\/pmj.2005.039032. PubMed PMID: 16597817; PubMed Central PMCID: PMC2579635.","journal-title":"Postgrad Med J"},{"key":"2420_CR9","doi-asserted-by":"publisher","unstructured":"Adesoba TP, Brown CC. Trends in the Prevalence of Lean Diabetes, Among US, Adults. 2015\u20132020. Diabetes Care. 2023;46(4):885-9. https:\/\/doi.org\/10.2337\/dc22-1847. PubMed PMID: 36763508.","DOI":"10.2337\/dc22-1847"},{"key":"2420_CR10","doi-asserted-by":"publisher","first-page":"04088","DOI":"10.7189\/jogh.13.04088","volume":"13","author":"HJ Yu","year":"2023","unstructured":"Yu HJ, Ho M, Liu X, Yang J, Chau PH, Fong DYT. Incidence and temporal trends in type 2 diabetes by weight status: a systematic review and meta-analysis of prospective cohort studies. J Glob Health. 2023;13:04088. https:\/\/doi.org\/10.7189\/jogh.13.04088. Epub 20230901.","journal-title":"J Glob Health"},{"issue":"8","key":"2420_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11892-018-1017-1","volume":"18","author":"UP Gujral","year":"2018","unstructured":"Gujral UP, Weber MB, Staimez LR, Narayan KMV. Diabetes among Non-overweight individuals: an emerging Public Health Challenge. Curr Diab Rep. 2018;18(8):60. https:\/\/doi.org\/10.1007\/s11892-018-1017-1. Epub 20180704.","journal-title":"Curr Diab Rep"},{"issue":"5","key":"2420_CR12","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1139\/H07-100","volume":"32","author":"A Vaag","year":"2007","unstructured":"Vaag A, Lund SS. Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention? Appl Physiol Nutr Metab. 2007;32(5):912\u201320. https:\/\/doi.org\/10.1139\/H07-100. PubMed PMID: 18059616.","journal-title":"Appl Physiol Nutr Metab"},{"key":"2420_CR13","doi-asserted-by":"publisher","unstructured":"Pluta W, Dudzi\u0144ska W, Lubkowska A. Metabolic Obesity in People with Normal Body Weight (MONW)-Review of Diagnostic Criteria. Int J Environ Res Public Health. 2022;19(2). Epub 20220106. https:\/\/doi.org\/10.3390\/ijerph19020624. PubMed PMID: 35055447; PubMed Central PMCID: PMC8776153.","DOI":"10.3390\/ijerph19020624"},{"issue":"8","key":"2420_CR14","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1093\/ajcn\/34.8.1617","volume":"34","author":"NB Ruderman","year":"1981","unstructured":"Ruderman NB, Schneider SH, Berchtold P. The metabolically-obese, normal-weight individual. Am J Clin Nutr. 1981;34(8):1617\u201321. https:\/\/doi.org\/10.1093\/ajcn\/34.8.1617. PubMed PMID: 7270486.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"2420_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1304501","volume":"370","author":"DK Tobias","year":"2014","unstructured":"Tobias DK, Pan A, Jackson CL, O\u2019Reilly EJ, Ding EL, Willett WC, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370(3):233\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1304501. PubMed PMID: 24428469; PubMed Central PMCID: PMC3966911.","journal-title":"N Engl J Med"},{"issue":"9","key":"2420_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.7326\/M14-1551","volume":"162","author":"P Costanzo","year":"2015","unstructured":"Costanzo P, Cleland JG, Pellicori P, Clark AL, Hepburn D, Kilpatrick ES, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Intern Med. 2015;162(9):610\u20138. https:\/\/doi.org\/10.7326\/M14-1551. PubMed PMID: 25938991.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2420_CR17","doi-asserted-by":"publisher","first-page":"101694","DOI":"10.1016\/j.cpcardiol.2023.101694","volume":"48","author":"K Nabrdalik","year":"2023","unstructured":"Nabrdalik K, Kwiendacz H, Dro\u017cd\u017c K, Irlik K, Hendel M, Wijata AM, et al. Machine learning predicts Cardiovascular events in patients with diabetes: the Silesia Diabetes-Heart Project. Curr Probl Cardiol. 2023;48(7):101694. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101694. Epub 20230314.","journal-title":"Curr Probl Cardiol"},{"issue":"6","key":"2420_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European Guidelines for Obesity Management in adults. Obes Facts. 2015;8(6):402\u201324. Epub 20151205. doi: 10.1159\/000442721. PubMed PMID: 26641646; PubMed Central PMCID: PMC5644856.","journal-title":"Obes Facts"},{"issue":"2","key":"2420_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000350627","volume":"6","author":"G Fr\u00fchbeck","year":"2013","unstructured":"Fr\u00fchbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM, et al. Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6(2):117\u201320. Epub 20130403. doi: 10.1159\/000350627. PubMed PMID: 23548858; PubMed Central PMCID: PMC5644725.","journal-title":"Obes Facts"},{"issue":"10","key":"2420_CR20","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953\u20132041. doi: 10.1097\/HJH.0000000000001940. PubMed PMID: 30234752.","journal-title":"J Hypertens"},{"key":"2420_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"ATF Members","year":"2019","unstructured":"Members ATF, ECfPG (CPG), Societies ENC. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.014. Epub 20190831.","journal-title":"Atherosclerosis"},{"issue":"5S","key":"2420_CR22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"KDIGOKDW Group","year":"2022","unstructured":"Group KDIGOKDW. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008. PubMed PMID: 36272764.","journal-title":"Kidney Int"},{"issue":"4S","key":"2420_CR23","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGOKCW Group","year":"2024","unstructured":"Group KDIGOKCW. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018. PubMed PMID: 38490803.","journal-title":"Kidney Int"},{"issue":"11","key":"2420_CR24","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","volume":"119","author":"C Zoccali","year":"2023","unstructured":"Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119(11):2017\u201332. https:\/\/doi.org\/10.1093\/cvr\/cvad083. PubMed PMID: 37249051; PubMed Central PMCID: PMC10478756.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"2420_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/ckj\/sfac199","volume":"16","author":"A Ortiz","year":"2023","unstructured":"Ortiz A, Wanner C, Gansevoort R, Council E. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Clin Kidney J. 2023;16(3):403\u20137. https:\/\/doi.org\/10.1093\/ckj\/sfac199. Epub 20221011.","journal-title":"Clin Kidney J"},{"issue":"1","key":"2420_CR26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12933-022-01672-9","volume":"21","author":"K Dro\u017cd\u017c","year":"2022","unstructured":"Dro\u017cd\u017c K, Nabrdalik K, Kwiendacz H, Hendel M, Olejarz A, Tomasik A, et al. Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach. Cardiovasc Diabetol. 2022;21(1):240. https:\/\/doi.org\/10.1186\/s12933-022-01672-9. Epub 20221112.","journal-title":"Cardiovasc Diabetol"},{"key":"2420_CR27","doi-asserted-by":"publisher","unstructured":"Nabrdalik K, Bisson A, Irlik K, Fauchier G, Ducluzeau PH, Lip GYH et al. Metabolically \u2018extremely unhealthy\u2019 obese and non-obese patients with diabetes and the risk of cardiovascular events: a French nationwide cohort study. Clin Res Cardiol. 2023. Epub 20231204. https:\/\/doi.org\/10.1007\/s00392-023-02344-8. PubMed PMID: 38047924.","DOI":"10.1007\/s00392-023-02344-8"},{"key":"2420_CR28","doi-asserted-by":"publisher","unstructured":"Bl\u00fcher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3). https:\/\/doi.org\/10.1210\/endrev\/bnaa004. PubMed PMID: 32128581; PubMed Central PMCID: PMC7098708.","DOI":"10.1210\/endrev\/bnaa004"},{"issue":"24","key":"2420_CR29","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1161\/CIRCULATIONAHA.114.009098","volume":"130","author":"W Zhao","year":"2014","unstructured":"Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Li W, Johnson J, et al. Body mass index and the risk of all-cause mortality among patients with type 2 diabetes mellitus. Circulation. 2014;130(24):2143\u201351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.009098. Epub 20141105.","journal-title":"Circulation"},{"issue":"6","key":"2420_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jama.2012.9282","volume":"308","author":"MR Carnethon","year":"2012","unstructured":"Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308(6):581\u201390. https:\/\/doi.org\/10.1001\/jama.2012.9282. PubMed PMID: 22871870; PubMed Central PMCID: PMC3467944.","journal-title":"JAMA"},{"issue":"1","key":"2420_CR31","doi-asserted-by":"publisher","first-page":"e0168247","DOI":"10.1371\/journal.pone.0168247","volume":"12","author":"Y Kwon","year":"2017","unstructured":"Kwon Y, Kim HJ, Park S, Park YG, Cho KH. Body Mass Index-related mortality in patients with type 2 diabetes and heterogeneity in obesity Paradox studies: a dose-response Meta-analysis. PLoS ONE. 2017;12(1):e0168247. https:\/\/doi.org\/10.1371\/journal.pone.0168247. Epub 20170103.","journal-title":"PLoS ONE"},{"issue":"11","key":"2420_CR32","doi-asserted-by":"publisher","first-page":"e48230","DOI":"10.7759\/cureus.48230","volume":"15","author":"R Pray","year":"2023","unstructured":"Pray R, Riskin S. The history and faults of the body Mass Index and where to look Next: A literature review. Cureus. 2023;15(11):e48230. https:\/\/doi.org\/10.7759\/cureus.48230. Epub 20231103.","journal-title":"Cureus"},{"key":"2420_CR33","doi-asserted-by":"publisher","unstructured":"Mirzai S, Carbone S, Batsis JA, Kritchevsky SB, Kitzman DW, Shapiro MD. Sarcopenic Obesity and Cardiovascular Disease: An Overlooked but High-Risk Syndrome. Curr Obes Rep. 2024. Epub 20240516. https:\/\/doi.org\/10.1007\/s13679-024-00571-2. PubMed PMID: 38753289.","DOI":"10.1007\/s13679-024-00571-2"},{"key":"2420_CR34","doi-asserted-by":"crossref","unstructured":"Sinclair AJ, Abdelhafiz AH, Multimorbidity. Frailty and Diabetes in Older people-identifying interrelationships and outcomes. J Pers Med. 2022;12(11). Epub 20221116. doi: 10.3390\/jpm12111911. PubMed PMID: 36422087; PubMed Central PMCID: PMC9695437.","DOI":"10.3390\/jpm12111911"},{"issue":"8","key":"2420_CR35","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1111\/dom.13303","volume":"20","author":"SV Arnold","year":"2018","unstructured":"Arnold SV, Kosiborod M, Wang J, Fenici P, Gannedahl G, LoCasale RJ. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab. 2018;20(8):2000\u20133. Epub 20180419. doi: 10.1111\/dom.13303. PubMed PMID: 29577540.","journal-title":"Diabetes Obes Metab"},{"issue":"20","key":"2420_CR36","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a Presidential Advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335. Epub 20231009. doi: 10.1161\/CIR.0000000000001184. PubMed PMID: 37807924.","journal-title":"Circulation"},{"issue":"5","key":"2420_CR37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/eurheartj\/ehx448","volume":"39","author":"C Lassale","year":"2018","unstructured":"Lassale C, Tzoulaki I, Moons KGM, Sweeting M, Boer J, Johnson L, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-european case-cohort analysis. Eur Heart J. 2018;39(5):397\u2013406. https:\/\/doi.org\/10.1093\/eurheartj\/ehx448. PubMed PMID: 29020414; PubMed Central PMCID: PMC6198928.","journal-title":"Eur Heart J"},{"issue":"6","key":"2420_CR38","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","volume":"46","author":"SP Laing","year":"2003","unstructured":"Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46(6):760\u20135. https:\/\/doi.org\/10.1007\/s00125-003-1116-6. Epub 20030528.","journal-title":"Diabetologia"},{"issue":"15","key":"2420_CR39","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Franz\u00e9n S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, et al. Mortality and Cardiovascular Disease in Type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1608664. PubMed PMID: 28402770.","journal-title":"N Engl J Med"},{"key":"2420_CR40","doi-asserted-by":"publisher","first-page":"9985836","DOI":"10.1155\/2024\/9985836","volume":"2024","author":"RK Yankah","year":"2024","unstructured":"Yankah RK, Anku EK, Eligar V, Sodium-Glucose. Cotransporter-2 inhibitors and Cardiovascular Protection among patients with type 2 diabetes Mellitus: a systematic review. J Diabetes Res. 2024;2024:9985836. Epub 20240511. doi: 10.1155\/2024\/9985836. PubMed PMID: 38766320; PubMed Central PMCID: PMC11102109.","journal-title":"J Diabetes Res"},{"issue":"17","key":"2420_CR41","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","volume":"142","author":"J Rangaswami","year":"2020","unstructured":"Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, et al. Cardiorenal Protection with the newer antidiabetic agents in patients with diabetes and chronic kidney Disease: A Scientific Statement from the American Heart Association. Circulation. 2020;142(17):e265\u201386. Epub 20200928. doi: 10.1161\/CIR.0000000000000920. PubMed PMID: 32981345.","journal-title":"Circulation"},{"issue":"22","key":"2420_CR42","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. Epub 20150917. doi: 10.1056\/NEJMoa1504720. PubMed PMID: 26378978.","journal-title":"N Engl J Med"},{"issue":"4","key":"2420_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. Epub 20181110. doi: 10.1056\/NEJMoa1812389. PubMed PMID: 30415602.","journal-title":"N Engl J Med"},{"issue":"21","key":"2420_CR44","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. Epub 20190919. doi: 10.1056\/NEJMoa1911303. PubMed PMID: 31535829.","journal-title":"N Engl J Med"},{"issue":"15","key":"2420_CR45","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413\u201324. Epub 20200828. doi: 10.1056\/NEJMoa2022190. PubMed PMID: 32865377.","journal-title":"N Engl J Med"},{"issue":"10","key":"2420_CR46","doi-asserted-by":"publisher","first-page":"e30787","DOI":"10.1016\/j.heliyon.2024.e30787","volume":"10","author":"M Rottura","year":"2024","unstructured":"Rottura M, Drago SFA, Gianguzzo VM, Molonia A, Pallio G, Scoglio R, et al. Chronic kidney disease progression in diabetic patients: real world data in general practice. Heliyon. 2024;10(10):e30787. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30787. Epub 20240506.","journal-title":"Heliyon"},{"key":"2420_CR47","doi-asserted-by":"publisher","unstructured":"Hayat J, Shah NP, Agarwala A, Khan MS, Butler J. GLP-1 receptor agonists and Cardiovascular Disease: what do clinicians need to know? Curr Atheroscler Rep. 2024. Epub 20240529. https:\/\/doi.org\/10.1007\/s11883-024-01214-6. PubMed PMID: 38809399.","DOI":"10.1007\/s11883-024-01214-6"},{"issue":"19","key":"2420_CR48","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. Epub 20160915. doi: 10.1056\/NEJMoa1607141. PubMed PMID: 27633186.","journal-title":"N Engl J Med"},{"key":"2420_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03015-5","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03015-5. Epub 20240525.","journal-title":"Nat Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02420-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02420-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02420-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:04:19Z","timestamp":1725368659000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02420-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2420"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02420-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Based on the decision of the Bioethics Committee of the Medical University of Silesia in Katowice, the need for ethical approval was waived (decision no. PCN\/0022\/KB\/126\/20).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave consent for the publication of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.Y.H.L. is a consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Anthos and Daiichi-Sankyo. No fees are received personally. G.Y.H..L is a NIHR Senior Investigator and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalised management of atrial fibrillation and stroke (grant agreement No 101136244) and ARISTOTELES project on artificial intelligence for management of chronic long term conditions (grant agreement No 101080189), which are all funded by the EU\u2019s Horizon Europe Research & Innovation programme. G.B. is Study Coordinator of ARISTOTELES (Applying ARtificial Intelligence to define clinical trajectorieS for personalized predicTiOn and early deTEction of comorbidity and muLtimorbidity pattErnS) Grant from Horizon Europe (HORIZON-HLTH-2022-STAYHLTH-01- Grant 101080189). G.B. received small speaker\u2019s fee from Bayer, Boston, Boehringer Ingelheim, Brystol Myers Squibb, Janssen, and Sanofi. UA has received honoraria from Eli Lilly, Procter & Gamble, Viatris, Grunenthal and Sanofi for educational meetings and funding for attendance to an educational meeting from Diiachi Sankyo. UA has also received investigator-led funding by Procter & Gamble and is a council member of the Royal Society of Medicine's Vascular, Lipid & Metabolic Medicine Section. HK received remunerations\/fees for activities on behalf of Sanofi-Aventis, Eli Lilly, Novo Nordisk, Servier, Astra-Zeneca, Boehringer-Ingelheim. JG received remunerations\/fees for activities on behalf of Sanofi-Aventis, Eli Lilly, Novo Nordisk, Servier, Astra-Zeneca, Boehringer-Ingelheim, Bioton, Polfa Tarchomin, Medtronic, Roche, and Abbott. KN received remunerations\/fees for activities on behalf of Sanofi-Aventis, Eli Lilly, Novo Nordisk, Servier, Astra-Zeneca, Boehringer-Ingelheim, Bioton, Polfa Tarchomin, Roche, and Abbott. All other authors report no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"326"}}